• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by PAVmed Inc.

    5/15/25 1:14:39 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care
    Get the next $PAVM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    PAVmed Inc.

    (Name of Issuer)


    Common Stock, Par Value $0.001 Per Share

    (Title of Class of Securities)


    70387R403

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    70387R403


    1Names of Reporting Persons

    FIRST MANHATTAN CO. LLC.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    700,000.00
    6Shared Voting Power

    14,100.00
    7Sole Dispositive Power

    700,000.00
    8Shared Dispositive Power

    14,100.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    714,100.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PAVmed Inc.
    (b)Address of issuer's principal executive offices:

    360 MADISON AVENUE, 25TH FLOOR, NEW YORK, NEW YORK, 10017.
    Item 2. 
    (a)Name of person filing:

    First Manhattan Co. LLC
    (b)Address or principal business office or, if none, residence:

    399 Park Avenue New York, NY 10022
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock, Par Value $0.001 Per Share
    (e)CUSIP No.:

    70387R403
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    714,100
    (b)Percent of class:

    4.25%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    700,000

     (ii) Shared power to vote or to direct the vote:

    14,100

     (iii) Sole power to dispose or to direct the disposition of:

    700,000

     (iv) Shared power to dispose or to direct the disposition of:

    14,100

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FIRST MANHATTAN CO. LLC.
     
    Signature:Jeremy Covino
    Name/Title:Chief Compliance Officer
    Date:05/15/2025
    Get the next $PAVM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on PAVmed with a new price target

    Cantor Fitzgerald initiated coverage of PAVmed with a rating of Overweight and set a new price target of $8.00

    3/30/21 6:22:24 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lake Street Capital reiterated coverage on PAVmed with a new price target

    Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously

    2/22/21 4:33:18 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Tasso Partners, Llc claimed ownership of 2,574,350 shares (SEC Form 3)

    3 - PAVmed Inc. (0001624326) (Issuer)

    3/14/25 7:53:09 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Agrawal Sundeep

    4 - PAVmed Inc. (0001624326) (Issuer)

    10/23/24 4:36:47 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Agrawal Sundeep

    4 - PAVmed Inc. (0001624326) (Issuer)

    9/20/24 4:13:39 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Announces Closing of Public Offering of Common Stock

    NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the closing of its previously announced underwritten public offering of 28,750,000 shares of its common stock, including 3,750,000 shares issued pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.00 per share. The total net proceeds from the offering, after deducting the underw

    9/11/25 9:17:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    SEC Filings

    View All

    PAVmed Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PAVmed Inc. (0001624326) (Filer)

    9/11/25 9:28:47 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PAVmed Inc. (0001624326) (Filer)

    8/14/25 8:00:39 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by PAVmed Inc.

    10-Q - PAVmed Inc. (0001624326) (Filer)

    8/13/25 8:04:24 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Leadership Updates

    Live Leadership Updates

    View All

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

    NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

    5/27/25 7:31:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Financials

    Live finance-specific insights

    View All

    Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

    Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advisory Committee ("CAC") Meeting convened by MolDX-participating Medicare Administrative Contractors as part of the reconsideration of Local Coverage Determination (LCD) L39256, "MolDX: Molec

    9/5/25 9:16:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 31, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, August 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's secon

    7/31/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 fi

    7/30/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    11/14/24 10:02:46 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    9/23/24 8:46:15 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    2/14/24 3:38:38 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care